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Abstract
p150, product of the SALL2 gene, is a binding partner of the polyoma virus large T antigen and a putative tumor suppressor.
p150 binds to the nuclease hypersensitive element of the c-MYC promoter and represses c-MYC transcription.
Overexpression of p150 in human ovarian surface epithelial cells leads to decreased expression, and downregulation to
increased expression, of c-MYC. c-MYC is repressed upon restoration of p150 to ovarian carcinoma cells. Induction of
apoptosis by etoposide results in recruitment of p150 to the c-MYC promoter and to repression of c-MYC. Analysis of data in
The Cancer Genome Atlas shows negative correlations between SALL2 and c-MYC expression in four common solid tumor
types.
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Introduction
Oncogenic DNA viruses target tumor suppressor genes of their
hosts for inactivation ostensibly to promote cell cycle progression
and to block apoptosis as essential steps in virus replication. These
functions are also critical for cell transformation and tumor
induction by these viruses [1]. The highly oncogenic mouse
polyoma virus (Py) stands apart from SV40 and other DNA tumor
viruses in failing to target p53 for inactivation or destruction. A
screen was previously designed to identify tumor suppressors or
other host factors with which Py must interact in order to replicate.
The product of the SALL2 gene (p150) was identified as a Py large
T binding protein using this screen [2]. p150 binds at the C-
terminus of Py large T in a region bearing no homology to SV40
large T. p150 blocks Py DNA replication and binding of p150 by
Py large T overcomes this inhibition. A Py mutant unable to bind
p150 is unable to replicate and fails to induce a broad spectrum of
tumors in the mouse [2]. Targeting of p150 by the human
papilloma virus HPV16 E6 oncoprotein has recently been
reported [3].
Evolutionarily conserved SALL genes encode multi-zinc finger
transcription factors that function in embryonic development in
invertebrate and vertebrate species [4] including man [5,6,7,8].
Unique within this family, SALL2 has been implicated as a
possible tumor suppressor [9,10]. SALL2 has growth arrest and
proapoptotic functions that overlap with those of p53. Specifically,
p150 binds to the p21
Cip1/Waf1 promoter in regions adjacent to the
known p53 binding sites and transactivates p21
Cip1/Waf1 in the
absence of p53 [9]. p150 also binds to the BAX promoter and
activates transcription [9,11]. Restoration of p150 to human
ovarian carcinoma cells deficient in p150 expression results in
partial inhibition of tumor growth in SCID mice accompanied by
elevated levels of p21
Cip1/Waf1 and BAX [9]. SALL2 has also been
recognized and characterized as a ‘quiescence factor’, essential for
arresting growth of human fibroblasts under conditions of serum
deprivation [12]. When treated with SALL2-siRNA, serum-
deprived cells fail to arrest [12]. Upon restoration of serum,
p150 is rapidly degraded as cells re-enter the cell cycle. Factors
that regulate SALL2 expression at the transcriptional and
posttranslational levels as a function of growth conditions have
been identified [13].
The DNA sequence specificity of binding by p150 has recently
been investigated [11]. The optimal consensus sequence for
binding in vitro is the heptanucleotide GGG(T/C)GGG. p150
binds to GC-rich elements related to this sequence present in the
promoter regions of p21
Cip1/Waf1 and BAX [11]. The present
investigation was undertaken to determine whether the proto-
oncogene c-MYC may come under negative regulation by p150,
consistent with the frequent overexpression of c-MYC in many
PLOS ONE | www.plosone.org 1 September 2012 | Volume 7 | Issue 9 | e46486forms of cancer and with the action of p150 as a putative tumor
suppressor.
Materials and Methods
Cells and transfections
HOSE cells were telomerase-immortalized, HPV E6-trans-
formed human ovarian surface epithelial cells [14,15]. Ovarian
carcinoma-derived RMUGS cells which are deficient in p150 [9]
were obtained from the American Type Culture Collection. Cells
were grown in DMEM with 10% fetal bovine serum. pcDNA 3.1
(Invitrogen) and pcDNA3.1-p150 were transfected with lipofecta-
mine 2000 (Invitrogen) into HOSE cells for 48 hours. Negative
control siRNA (Invitrogen, #45-2001) and SALL2 siRNA
(Invitrogen # HSS 109406) were transfected with oligofectamine
(Invitrogen) for 48 hours.
Antisera
Polyclonal antisera were raised in rabbits against the N-terminus
(amino acids 1–550) and the C-terminus (amino acids 717–1005)
of human p150 purified as GST fusions [11]. Antisera were
purified by flow through over a GST column and binding to Staph
A agarose beads. c-MYC epitope antibody was from Santa Cruz ;
it recognizes the 62 kDa c-Myc2 protein referred to as c-MYC in
this study. The anti-GAPDH was from Calbiochem.
Western blots
Immunoblotting was carried out on cell extracts using an
Odyssey infrared imaging system (LI-COR Biosciences, Lincoln,
NE). Intensity values were determined with LI-COR Odyssey
software (Li-COR Biosciences).
Chromatin immunoprecipitation (ChIP)
ChIP was performed as described [16] with slight modifications.
For binding of endogenous p150 to the c-MYC promoter in
HOSE cells, Staph A-agarose beads coated with N- or C-terminal
p150 antibody or normal rabbit sera were used. Immunoselected
chromatin fragments were subjected to PCR (32 cycles) with a
primer set (59-CTCTCTTACTCTGTTTACATCCTAG and 59-
CTGGAATTACTACAGCGAGTTAG) for c-MYC amplifica-
tion. Band intensities of the amplified DNA were revealed on a 1%
agarose gel. ChIP assays were performed on HOSE cells with or
without prior si-RNA SALL2 knockdown. Control- or SALL2-
siRNA was introduced into HOSE cells. At 48 hours post
transfection, sonicated chromatin was immunoprecipitated with
N-terminal p150 antibody. qRT-PCR assays were performed with
primer sets (c-MYC promoter, 59-GCGTAGTTAATT-
CATGCGGCTCTC and 59- CCCACGCCCTCTGCTTTGG-
GAACC; aldolase A promoter, 59- CGGTCTGTTCGTTGCA-
CAGAGTAG and 59-GTTGAGGCAGTAGACAGAGAAAGC).
The threshold values of each sample were normalized with those
of corresponding 1% input control sample. To determine the
effects of etoposide on p150-binding to the c-MYC promoter,
HOSE cells were transfected with p150 expression vector for
48 hours and incubated for an additional 22 hours with etoposide
(40 mM ) to induce apoptosis. ChIP was carried out with anti-N-
terminal p150 antibody. Immunopurified chromatin fragments
were amplified by RT-PCR.
Quantitative RT-PCR
Total RNA was isolated using RNeasyH kit (Qiagen), reversed
transcribed using QuantiTect Reverse Transcription Kit (Qiagen)
and quantitated by RT-PCR using specific primers: SALL2 F: 59-
CACGAATCCGAGAGGAGCTCTC, R: 59-CACCATTA-
Figure 1. GST-p150 binds to the c-MYC promoter region in vitro
and in vivo. (A) The GC-rich nuclease hypersensitive element NHE III1 of
the human c-MYC promoter. Consensus binding sites for p150 are
underlined. Approximate positions of transcriptional start sites are
shown (P1, P2). (B) An electrophoretic mobility shift assay shows
binding of GST-p150 to the labeled NHE III1 and to the consensus
binding sequence (CS) GGGTGGG- as control ( ). 506molar excess of
unlabeled NHE III1 and CS compete for binding while the unrelated
Oct1 olionucleotide does not. (C) Chromatin immunoprecipitation
assays with antibodies to the N- and C-terminal portions of p150 show
binding of endogenous p150 to the NHE III1 region of the c-MYC
promoter in HOSE cells. (D) SALL2-knockdown leads to reduced binding
of p150 to the c-MYC promoter. HOSE cells were treated with SALL2
siRNA or control oligonucleotide and followed by chromatin immuno-
precipitation and quantitative RT-PCR assays. The threshold cycle values
of immunoprecipitates were normalized to those of 1% input control
samples. The human aldolase A promoter region was included as a
negative control. Estimates of binding were based on triplicate samples.
** denotes p,0.01 based on Student t test run on HOSE cells treated
with SALL2-siRNA or control RNA.
doi:10.1371/journal.pone.0046486.g001
SALL2 and c-MYC
PLOS ONE | www.plosone.org 2 September 2012 | Volume 7 | Issue 9 | e46486Figure 2. p150 represses c-MYC expression. (A) Left - overexpression of p150 results in reduced c-MYC expression in HOSE cells shown by
quantitative RT PCR. Right – immunoblotting for c-MYC. (B) Left - siRNA-knockdown of endogenous SALL2 in HOSE cells leads to increased c-MYC
expression by quantitative RT PCR. Right - immunoblotting for c-MYC. (C) Left - Human c-MYC promoter region and luciferase reporters used in
promoter activity assays. The NHE region (2142 to 2100) including p150 consensus binding sites (underlined) was deleted in the reporter myc-Luc-
SALL2 and c-MYC
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CAGCTTGTAC, R: 59CGAGCTGCTGTCGTTGAGAG; Al-
dolase A F: 59-CGCAGAAGGGGTCCTGGTGA, R: 59-
CAGCTCCTTCTTCTGCTCCGGGGT. qRT-PCR was car-
ried out on a Roche LightCycler 480 using SYBR Green Master
Mix. The data were analyzed by the comparative CT (DDCT)
method and quantitated relative to the aldolase A gene and
normalized to the controls.
Gel shift assays for binding of p150 to the c-MYC
promoter
Oligonucleotides containing the NHE III1 of the human c-
MYC promoter (59-TGGGGAGGGTGGGGAGGGTGGG-
GAAGG), the p150 consensus binding sequence (CS) (59-
GGATCACTGGGTGGGAATCACGCT) and Oct1 binding site
(59-TGTCGAATGCAAATCACTAGAA) and their complemen-
tary sequences were purchased from IDT (Coralville, Iowa).
Annealed complementary fragments were radiolabeled with
[c-
32P] dATP. Binding reactions were carried out in the presence
of 100 ng purified GST or GST tagged p150 in reaction buffer
containing 10 mM HEPES (pH 7.5), 25 nM KCl, 2.5 mM MgCl,
5 ml ZnCl, 3% glycerol, 2 mg BSA and 200 ng Poly(dA-dT). For
specific and nonspecific competition, 50 molar excess unlabeled
oligonucleotides were added to the mixture.
Luciferase reporter assay
Reporter plasmids myc-Luc and myc-Luc-DNHE with and
without the NHE III1 respectively were constructed using
two primer sets: myc-Luc, 59-ATAGATCTCTCTTACTC-
TGTTTACATCCTAGAGC and 59-ATAAGCTTCCGGGA-
GGGGCGCTTATGGGGAGGG; myc-Luc-DNHE, 59- AT-
AAGCTTCCTCAGCCGTCCAGACCCTCGCATT and 59-
ATAAGCTTGGAGACTCAGCCGGGCAGCCGAGCAC.
Amplified fragments were cloned into pGL3 and the constructs
verified by sequencing. The vectors myc-Luc and myc-Luc-
DNHE and pRL-TK were introduced into HOSE cells
pretreated with control siRNA or SALL2-siRNA oligonucleo-
tides. For a dose-dependent reporter assay, RMUGS cells were
transfected with myc-Luc, pRL-CMV and pcDNA or pcDNA-
p150. After 48 hours of incubation at 37uC, the transfected cells
were subjected to luciferase activity assays (Dual-Luciferase
Reporter System; Promega, Madison, WI). Firefly luciferase
values were normalized to those of Renilla luciferase.
Correlations between SALL2 and c-MYC expression levels
in tumors
Gene expression data from The Cancer Genome Atlas (TCGA)
were accessed and downloaded from TCGA Data Portal (https://
tcga-data.nci.nih.gov/tcga/). Cancer types selected for correlation
analysis were those having more than 100 samples with Level 3
Expression-Gene data (https://tcga-data.nci.nih.gov/tcga/
tcgaDataType.jsp) and ones known to arise from tissues that
normally express SALL2 based on data in the mouse [2] and
human ovarian epithelial cells [9]. This resulted in selection of
ovarian serous cystadenocarcinoma (OVCA), glioblastoma multi-
forme (GBM), lung squamous cell carcinoma (LUSC) and breast
invasive carcinoma (BRCA). For all data sets, tumor specimen-
specific SALL2 and MYC expression levels were retrieved,
compiled, and entered into the SAS JMP Pro 9.0.0 software
package. Scatter plots of SALL2 by MYC were generated using
the software’s ‘‘Fit Y by X’’ command. Pearson correlation
coefficients and associated p values were calculated using the
default Restricted Maximum Likelihood (REML) method.
Results and Discussion
p150 binds to the NHE III1 of the c-MYC promoter
Several approaches have been used to determine whether p150
binds to the c-MYC promoter region and regulates its expression.
Initial focus was on the GC-rich nuclease-hypersensitive element
(NHE III1) as a key regulator of c-MYC expression. NHE III1 has
tandem repeats of the optimal consensus binding sequence
established for p150 [11] (Figure 1A). The NHE III1 can adopt
a four stranded ‘quadruplex’ secondary structure known to be
targeted by zinc-finger transcription factors and to be associated
with silencing of c-MYC transcription [17,18]. A recombinant
GST fusion protein (GST-p150) was expressed and purified from
293 cells [11]. GST-p150 was used in a gel shift assay with
radioactive NHE III1 (Figure 1B). GST-p150 clearly binds to the
NHE III1 as well as to the consensus sequence (CS) oligonucleotide
as a control. A 50-fold molar excess of unlabeled NHE III1 or CS
oligonucleotide competed for binding by the labeled NHE III1
while the unrelated Oct1 oligonucleotide did not.
DNHE. Right - siRNA to SALL2 in HOSE cells results in increased expression of myc-Luc but has no effect on myc-Luc-DNHE. (D) Expression of
exogenous p150 in p150-deficient RMUGS ovarian cancer cells leads to decreased expression of the reporter myc-Luc. All histograms are based on
triplicate determinations. * and ** denote p,0.05 and p,0.01, respectively, comparing means of experimental and control.
doi:10.1371/journal.pone.0046486.g002
Figure 3. An apoptotic signal leads to increased binding of p150 to the c-MYC promoter. (A) Left - Etoposide-treated HOSE cells were
monitored for apoptosis by caspase-3 activation. Middle - Quantitative RT-PCR shows a moderate increase in SALL2 and a large decrease in c-MYC
expression following etoposide treatment. Right - ChIP followed by qRT-PCR shows increased binding of p150 to the c-MYC promoter in etoposide-
treated cells. All histograms are based on triplicate determinations. ** denotes p,0.01 comparing means of experimental and control.
doi:10.1371/journal.pone.0046486.g003
SALL2 and c-MYC
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vivo, chromatin immunoprecipitation was carried out using
established human ovarian surface epithelial cells (HOSE).
Binding of endogenous p150 to a region of the c-MYC promoter
encompassing the NHE III1 was evident using either of two
polyclonal antibodies to the human protein (Figure 1C). SALL2
knockdown resulted in a decreased level of p150 binding to the c-
MYC promoter region (Figure 1D).
p150 negatively regulates c-MYC expression
To investigate whether binding of p150 to the c-MYC promoter
results in activation or repression of c-MYC, levels of SALL2
expression were manipulated in HOSE cells and in RMUGS, an
ovarian carcinoma-derived cell line lacking expression of p150 [9].
Overexpression of p150 in HOSE cells led to reduced levels of c-
MYC RNA and a commensurate decrease in levels of the protein
(Figure 2A). si-RNA targeting of SALL2 was previously shown to
promote G1RS progression in these cells [9]. This treatment also
led to increases in c-MYC mRNA (Figure 2B, left panel) and
protein (Figure 2B, right panel).
HOSE cells pretreated with si-SALL2 or control RNA
oligonucleotide were transfected with luciferase reporters with
and without the NHE III1 (Figure 2C, left) and a pRL-TK-Renilla
control vector for normalization. si-SALL2 RNA gave rise to
increased expression of the NHE III1 reporter (Figure 2C, right).
The ability of p150 to repress c-MYC expression was dependent
on retention of the NHE III1 as the reporter plasmid lacking NHE
III1 showed no response to si-SALL2 (Figure 2C, right). When
RMUGS cells lacking p150 were transfected with increasing
Figure 4. SALL2 by c-MYC expression scatterplots for cancer types in The Cancer Genome Atlas. (A) OVCA - ovarian serous
cystadenocarcinoma. (B) GBM – glioblastoma multiforme. (C ) BRCA – breast invasive carcinoma. (D) LUSC – lung squamous cell carcinoma.
n=number of samples; r=Pearson correlation coefficient; p=p-value of the correlation. The lines shown are those of best fit.
doi:10.1371/journal.pone.0046486.g004
SALL2 and c-MYC
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myc -Luc reporter were progressively reduced (Figure 2D).
These results demonstrate that p150 binds to the NHE III1 of
the c-MYC promoter in vitro and in vivo and represses c-MYC
transcription. The degree of transcriptional repression of c-MYC
by p150 is relatively modest. Expression of c-MYC is tightly
regulated, with small and often transient increases leading to
cellular proliferation [19,20]. Consistent with these results are
earlier findings that downregulation of SALL2 stimulates growth
of HOSE cells and that restoration of SALL2 in ovarian
carcinoma cells results in suppression of tumor growth [9].
An apoptotic signal leads to increased binding of p150 to
the c-MYC promoter
c-MYC can regulate apoptosis either positively or negatively
depending on cell type and physiological conditions [21]. HOSE
cells were treated with etoposide (40 mM for 22 hours) to induce
apoptosis. A fluorimetric assay for caspase-3 was used to confirm
the apoptotic response (Figure 3, left panel). Etoposide-treated cells
were assayed for SALL2 and c-MYC mRNA. SALL2 was slightly
induced and c-MYC strongly repressed following etoposide
treatment (Figure 3, middle panel). The strong reduction in c-
MYC RNA is most likely due in large part to p53 which is known
to repress c-MYC [22,23]. HOSE cells show a robust p53 response
to etoposide (Figure S1). Chromatin immunoprecipitation with
anti- p150 followed by qRT-PCR showed that etoposide treatment
led to increased binding of p150 to the c-MYC promoter (Figure 3,
right panel). Thus, recruitment of p150 to the c-MYC promoter
occurs as part of a response to an apoptotic stimulus in HOSE
cells. In other cell systems, modest increases in c-MYC expression
lead to a proliferative response, while high levels of expression
have been linked to tumor suppression and apoptosis [24,25].
Negative regulation of c-MYC by SALL2 may function to
maintain c-MYC levels within a normal range, avoiding thresholds
that lead to overproliferation or apoptosis.
SALL2 and c-MYC expression in tumors
Overexpression of c-MYC due to increased transcription or
DNA amplification accompanies the development of many forms
of human cancer including ovarian [26,27,28,29]. Transcriptional
repression of c-MYC coupled with activation of p21
Cip1/Waf1 and
BAX by p150 constitute powerful growth inhibitory and
proapoptotic functions consistent with action of SALL2 as a
tumor suppressor. To determine whether overexpression of c-
MYC is correlated with reduced expression of SALL2 in tumors,
levels of SALL2 and c-MYC expression in The Cancer Genome
Atlas were accessed. Four tumor types were selected for analysis
based on their derivations from normal tissues known to express
p150 in the mouse [2] and on high levels of expression in normal
human ovarian surface epithelial cells (HOSE). These are ovarian
serous cystadenocarcinoma (OVCA), glioblastoma multiforme
(GBM), breast invasive carcinoma (BRCA), and lung squamous
cell carcinoma (LUSC). These tumor types exhibit highly
significant negative correlations between SALL2 and c-MYC
expression. Inverse correlations were of similar magnitude, with
Pearson coefficients (r) ranging from 2.195 for GBM to 2.273 for
LUSC (Figure 4). Acute myeloid leukemia (AML) was analyzed as
a control as there is currently no evidence for SALL2 expression in
normal spleen [2] or other lymphoid tissue. For AML the negative
correlation is not significant (r=20.065, n=197, p=.3677).
Taken together, these results suggest that repression of c-MYC by
SALL2 may contribute to a role of the latter in suppressing these
forms of cancer. They point as well to the need for further
understanding of the molecular functions of SALL2.
Supporting Information
Figure S1 Etoposide induces a strong p53 response in
HOSE cells. HOSE cells were treated with either DMSO or
etoposide (40 mM) for 7 hours. Cells were lysed in PBS with 1%
NP40, protease and phosphatase inhibitors and subjected to a
western analysis. Anti-p150, GAPDH and phospho-specific p53
antibodies were used.
(TIF)
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